Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002058093-25-000008
Filing Date
2025-08-13
Accepted
2025-08-13 18:00:31
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8055
  Complete submission text file 0002058093-25-000008.txt   9906
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Subject) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94331 | Film No.: 251213315
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 EAST BROWARD BLVD SUITE 1105 FORT LAUDERDALE FL 33301
Business Address 200 EAST BROWARD BLVD SUITE 1105 FORT LAUDERDALE FL 33301 561-302-1101
INFINITUM ASSET MANAGEMENT, LLC (Filed by) CIK: 0002058093 (see all company filings)

EIN.: 832538611 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G